Identifying accumulation of resistance-associated mutations during tuberculosis treatment


This project monitors the effects of inappropriate initial therapy for multidrug-resistant tuberculosis (MDR-TB) on the development of additional drug resistance that will jeopardize successful treatment. Inappropriate treatment is defined in terms of treatment with drugs for which there is proven resistance, as well as inadequate dosing of the drugs. The project therefore includes detailed pharmacokinetic/pharmacodynamic assessments, and whole genome sequencing.

Patients are recruited consecutively from MDR-TB treatment centers in Moldova, Belarus, and the Netherlands. Results will be directly relevant for future treatment and monitoring guidelines.

Funding: The Netherlands Organisation for Health Research and Development (ZonMw)

Project partners: National Institute for Public Health and the Environment (RIVM), the Netherlands; University Hospital Groningen, the Netherlands; The Republic Scientific and Practical Center of Pulmonology and Tuberculosis Dolginovski, Belarus; Institute of Phthisiopneumology of Ministry of Health, Labour and Social Protection of the Republic of Moldova, Moldova

Timing: 2018 -

Frank van Leth
Associate Professor, Head section International Health